SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13. SUBSEQUENT EVENTS The Company has evaluated subsequent events and transactions for potential recognition or disclosure from the balance sheet date through August 14, 2025, the issuance date of the unaudited consolidated financial statements, and has not identified any additional items requiring disclosure except as noted below. Sales Agreement with A.G.P./Alliance Global Partners On July 3, 2025, the Company entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”), pursuant to which the Company may issue and sell from time to time up to $50,000,000 of shares of common stock through the Agent as the Company’s sales agent pursuant to the Company’s effective shelf registration statement on Form S-3 filed on June 20, 2025, and the prospectus supplement dated July 3, 2025. Sales of the Company’s common stock through the Agent have been and will be made by any method that is deemed to be an “at-the-market” equity offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Each time the Company wishes to issue and sell common stock under the Sales Agreement, the Company will provide a placement notice to the Agent containing the parameters in accordance with which shares are to be sold. The Agent will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the common stock from time to time, based upon the Company’s instructions. The Company is not obligated to make any sales of common stock under the Sales Agreement. The Company will pay the Agent a commission on the gross proceeds. Between July 3, 2025 and August 13, 2025, the Company sold an aggregate of approximately 2.3 million shares of common stock under the Sales Agreement at a weighted average price per share of $1.15, resulting in gross proceeds of $2.60 million. After deducting total expenses of approximately $70,000, including commission to the Agent of approximately $65,000, net proceeds to the Company were $2.53 million. Settlement of Accrued Interest under the Loan Agreement On July 21, 2025, the Company issued 43,042 shares of common stock in settlement of interest payable on draws under the Loan Agreement. This issuance settled all accrued interest payable on the Loan Agreement through July 16, 2025. KRHP Grant In August 2025, the Company received a grant of $1.0 million from KRHP to advance Tevogen.AI.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2025

NOTE 13. SUBSEQUENT EVENTS

The Company has evaluated subsequent events and transactions for potential recognition or disclosure from the balance sheet date through August 14, 2025, the issuance date of the unaudited consolidated financial statements, and has not identified any additional items requiring disclosure except as noted below.

Sales Agreement with A.G.P./Alliance Global Partners

On July 3, 2025, the Company entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”), pursuant to which the Company may issue and sell from time to time up to $50,000,000 of shares of common stock through the Agent as the Company’s sales agent pursuant to the Company’s effective shelf registration statement on Form S-3 filed on June 20, 2025, and the prospectus supplement dated July 3, 2025. Sales of the Company’s common stock through the Agent have been and will be made by any method that is deemed to be an “at-the-market” equity offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Each time the Company wishes to issue and sell common stock under the Sales Agreement, the Company will provide a placement notice to the Agent containing the parameters in accordance with which shares are to be sold. The Agent will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the common stock from time to time, based upon the Company’s instructions. The Company is not obligated to make any sales of common stock under the Sales Agreement. The Company will pay the Agent a commission on the gross proceeds.

Between July 3, 2025 and August 13, 2025, the Company sold an aggregate of approximately 2.3 million shares of common stock under the Sales Agreement at a weighted average price per share of $1.15, resulting in gross proceeds of $2.60 million. After deducting total expenses of approximately $70,000, including commission to the Agent of approximately $65,000, net proceeds to the Company were $2.53 million.

Settlement of Accrued Interest under the Loan Agreement

On July 21, 2025, the Company issued 43,042 shares of common stock in settlement of interest payable on draws under the Loan Agreement. This issuance settled all accrued interest payable on the Loan Agreement through July 16, 2025.

KRHP Grant

In August 2025, the Company received a grant of $1.0 million from KRHP to advance Tevogen.AI.